A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 1, 2001, Pages 7-13

  Lu, Jing ^a   Kuritzkes, Daniel R ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Fitness; HIV 1; Polymerase chain reaction; Viral

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ENZYME VARIANT; HISTIDINOL DEHYDROGENASE; INTEGRASE; LAMIVUDINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL RESEARCH; ENZYME ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; MARKER GENE; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; VIRUS RECOMBINANT; VIRUS RESISTANCE;

EID: 0035330599     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200105010-00002     Document Type: Article

References (21)

1. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
2. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
3. Relative replicative fitness of zidovudine-resistance human immunodeficiency virus type 1 isolates in vitro
4. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
5. Measuring the replicative fitness of recombinant HIV-1 vectors expressing protease and reverse transcriptase derived from patient viruses
6. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-1 infected patients with detectible viremia
7. Rapid decline in detectability of HIV-1 drug-resistance mutations after stopping therapy
8. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
9. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
10. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
11. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
12. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance
13. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type I reverse transcriptase
14. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
15. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
16. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome
17. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
18. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
19. Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis
20. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
21. High rate of recombination throughout the human immunodeficiency virus type-1 genome